21 May 2024 in Research Square
RCRaylane Gonçalves Cambui
LOLeonardo Teixeira de Oliveira
Leonardo Teixeira de Oliveira
+1
Inflammasome genetics affect several multifactorial diseases' development and severity, but the exact mechanism and cell types involved are mainly unknown. Recent findings have demonstrated the activation of caspase-1 and the release of IL-1β in B lymphocytes, leading us to hypothesize that genetic variants within the inflammasome may influence B cell functions and contribute to pathological immune responses. We previously reported the significance of NLRP3 and its variants in the dysregulation of B cells during chronic HIV infection. Here, we demonstrate that the inflammasome activation in human CD19+ cells is influenced by NLRP1 genetic variants yet associated with B cell-mediated diseases. The DPP-9 inhibitor ValBoro-Pro (VbP; Talabostat) was used to stimulate the two inflammasome sensors, NLRP1 and CARD8. First, we demonstrated that VbP induces caspase-1-dependent pyroptosis, but not IL-1β release, in CD19+ cells. Then, we evaluated the impact of common functional variants in NLRP1 and CARD8 genes on inflammasome activation in those cells. Therefore, our study identifies NLRP1 missense variants that impact B lymphocyte response to DPP9 inhibition. This implies a potential direct association between NLRP1 variants, B cell-mediated diseases, such as autoimmune and allergic conditions, and cancer.
3 January 2024 in Research Square
RCRaylane Gonçalves Cambui
+1
Chronic HIV infection leads to persistent immune activation and inflammation, which can impair the function of CD8+ T cells and their immune competence against infections and tumours. Independently from anti-retroviral treatment, in HIV patients, circulating leukocytes exhibit heightened expression of exhaustion markers and inflammasome-related genes. This study delves into the dysregulation of the inflammasome in CD8+ T lymphocytes of HIV-infected individuals and explores its impact on cell functionality, contributing to persistent inflammation. Our findings demonstrate that HIV CD8+ cells present a basal moderate activation of caspase-1, further increased by DPP-8/9 inhibition and TCR stimulation through activating the NLRP1/ASC and NLRP3/ASC pathways, respectively. Due to inflammasome activation, the HIV CD8+ T cells undergo GSDMD-induced pyroptosis. Compared with healthy donors’ CD8+ T cells, we observed resistance to NLRP1/caspase-1/GSDMD pyroptosis in HIV cells, compatible with the constitutive activation state of those cells. Moreover, the activation of the inflammasome is directly correlated with IFN-Ɣ secretion and with the expression of exhaustion markers on CD8+ T cells. Genotype-guided assays confirmed the presence of NLRP1 and NLRP3 inflammasomes in CD8+ T cells and revealed differential activation in HIV patients. In summary, we confirmed the presence of NLRP1 and NLRP3 inflammasomes in CD8+ T cells. We addressed how they are differentially activated in HIV patients, suggesting the inflammasome as a potential novel therapeutic target for HIV-related chronic inflammation. Keywords: HIV, CD8+ lymphocytes, inflammasome, pyroptosis, NLRP3, NLRP1, CARD8.